REPL241115C15000
- 0.20
- 0.000.00%
Replimune Newsroom
Press Release: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $17
J.P. Morgan analyst Anupam Rama maintains $Replimune(REPL.US)$ with a buy rating, and adjusts the target price from $14 to $17.According to TipRanks data, the analyst has a success rate of 46.9% and
Jefferies Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $16
Jefferies analyst Roger Song maintains $Replimune(REPL.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 35.7% and a total
Jefferies Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $16
Jefferies analyst Roger Song maintains $Replimune(REPL.US)$ with a buy rating, and adjusts the target price from $12 to $16.According to TipRanks data, the analyst has a success rate of 35.7% and a
Express News | Replimune Group Inc : Jefferies Raises Target Price to $16 From $12
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
HC Wainwright & Co. Reiterates Buy on Replimune Group, Maintains $17 Price Target
Replimune Group Says Potential Melanoma Treatment Study Yielded Positive Results
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
Barclays analyst Peter Lawson maintains $Replimune(REPL.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of 45.0% and a total
Reported Sunday, Replimune Announced Primary Analysis Results From IGNYTE Clinical Trial Of RP1 In Combination With Nivolumab For Anti-PD1 Resistant Melanoma At The 2024 ESMO Congress
Express News | Replimune Group - Overall Response Rate (Orr) Was 33.6% by Modified Recist (Mrecist) 1.1 Criteria, Primary Endpoint as Defined in Protocol
Express News | Replimune Group Inc - Injected and Non-Injected Lesions Responded With Similar Frequency, Depth, Duration and Kinetics
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $14
BMO Capital analyst Evan Seigerman maintains $Replimune(REPL.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 52.2% and a
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright analyst Robert Burns maintains $Replimune(REPL.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of 26.9% and a
Express News | Replimune Announces Positive Pre-Bla Meeting With FDA and Confirms Bla Submission on Track for 2H 2024